SOUTH SAN FRANCISCO, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced that Nassim Usman, Ph.D., President and CEO of Catalyst, will present at the Jefferies 2015 Global Healthcare Conference in New York on Tuesday, June 2, 2015, at 3:00 p.m. Eastern Time.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel products based on engineered human proteases to address serious unmet medical needs in multiple high value indications. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d/PF-05280602, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. Catalyst is privately held and backed by leading venture firms including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Innovation – JJDC, Inc., Morgenthaler Ventures, Rosetta Capital and Sofinnova Ventures. As previously announced, Catalyst has entered into a definitive agreement with Targacept, Inc. (Nasdaq:TRGT) to merge the two companies. The merger is expected to close in the third quarter of 2015. For more information, please visit www.catbio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this press release regarding our strategy, future operations, and plans are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the timing and completion of Catalyst’s proposed merger with Targacept, Inc. and the development and potential benefits of Catalyst’s product candidates. Actual results or events could differ materially from the plans, intentions expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including the risks described in the “Risk Factors” section of the Registration Statement on Form S-4 filed by Targacept with the SEC. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.
CONTACT: Investors: Catalyst Biosciences, Inc. Nassim Usman, Ph.D. CEO +1.650.266.8674 nusman@catbio.com Media: Denise Powell Red House Consulting, LLC +1.510.703.9491 denise@redhousecomms.com
Help employers find you! Check out all the jobs and post your resume.
